Sirnaomics Ltd., a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today that it has sealed $105 million in a Series E financing. This round of funding was led by Rotating Boulder Fund, an investor that has been supporting the company since its Series B round, with participation from existing investors and a well-recognized syndicate of new investors.